Jan Mikkelsen
Fortune : 102 M $ au 31/05/2026
Fortune : 102 M $ au 31/05/2026
M. Jan M. Mikkelsen est directeur général et directeur d'Ascendis Pharma Endocrinology Division A/S, président, directeur général et directeur exécutif d'Ascendis Pharma A/S, directeur général d'Ascendis Pharma Bone Diseases A/S et directeur général d'Ascendis Pharma Growth Disorders AS. Il est membre du conseil d'administration d'Ascendis Pharma Endocrinology Division A/S, d'Ascendis Pharma A/S et de Visen Pharmaceuticals (Shanghai) Co. Ltd. Auparavant, M. Mikkelsen a occupé les postes de président-directeur général de LifeCycle Pharma A/S, de président de la division pharmaceutique de Maxygen, Inc. et de co-président-directeur général de Profound Pharma AS, ainsi que de vice-président de la découverte de protéines chez Novo Nordisk A/S. Il a obtenu son diplôme de premier cycle à l'université du Danemark du Sud.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASCENDIS PHARMA A/S -.--% | 18/03/2026 | 453 403 ( -.--% ) | 102 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ASCENDIS PHARMA A/S | Fondateur | 21/09/2006 |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Directeur Général | 29/06/2012 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Directeur/Membre du Conseil | - |
Ascendis Pharma Bone Diseases A/S | Directeur Général | - |
Ascendis Pharma Growth Disorders AS | Directeur Général | - |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm focuses on pharmaceuticals, healthcare services and medical products & distribution sectors. It provides financing for growth and transformation transactions. | Consultant / Advisor | 01/01/2022 |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Président | 01/01/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| VISEN PHARMACEUTICALS | Directeur/Membre du Conseil | 27/06/2025 |
| VELOXIS PHARMACEUTICALS A/S | Directeur Général | 01/01/2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 13 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States. The firm focuses on pharmaceuticals, healthcare services and medical products & distribution sectors. It provides financing for growth and transformation transactions. | Finance |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Southern Denmark
University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Manufactures endocrine pharmaceutical products | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Health Technology |
Ascendis Pharma Bone Diseases A/S | |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national